We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-15.01%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$461M
AUM Growth
-$222M
Cap. Flow
-$108M
Cap. Flow %
-23.46%
Top 10 Hldgs %
59.88%
Holding
143
New
25
Increased
20
Reduced
27
Closed
54

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$24.9M
2
VTRS icon
Viatris
VTRS
+$13.9M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.4M
4
PFE icon
Pfizer
PFE
+$7.53M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$4.18M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$21.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$8.36M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.09M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$5.76M
5
INCY icon
Incyte
INCY
+$5.6M

Sector Composition

Rank Sector Weight
1 Healthcare 62.23%
2 Technology 3.77%
3 Utilities 2.89%
4 Communication Services 2.27%
5 Financials 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTN
76
Palatin Technologies
PTN
$13.7M
$1.22M 0.27%
1,812
-694
-28% -$451K
ABEO icon
77
Abeona Therapeutics
ABEO
$366M
$1.2M 0.26%
18,722
-5,278
-22% -$350K
ATXS
78
DELISTED
Astria Therapeutics
ATXS
$1.16M 0.25%
3,834
+2,488
+185% +$858K
CPRX
79
DELISTED
Catalyst Pharmaceutical
CPRX
$1.06M 0.23%
905,000
-550,000
-38% -$853K
PTLA
80
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.02M 0.22%
50,000
-35,500
-42% -$1.13M
ALDX icon
81
Aldeyra Therapeutics
ALDX
$92.9M
$999K 0.22%
238,500
– –
AXSM icon
82
Axsome Therapeutics
AXSM
$11.2B
$938K 0.2%
109,069
-110,931
-50% -$1.02M
MNKD icon
83
CALL
MannKind Corp
MNKD
$1.21B
$746K 0.16%
92,720
-59,280
-39% -$339K
IGLD
84
DELISTED
Internet Gold-Golden Lines Ltd
IGLD
$678K 0.15%
+503
New +$649K
OCRX
85
DELISTED
Ocera Therapeutics, Inc.
OCRX
$549K 0.12%
186,800
-363,200
-66% -$1.04M
ALPN
86
DELISTED
Alpine Immune Sciences Inc
ALPN
$333K 0.07%
19,975
-37,912
-65% -$759K
SBBP
87
DELISTED
Strongbridge Biopharma plc.
SBBP
$277K 0.06%
60,718
-121,100
-67% -$546K
TBRA
88
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$264K 0.06%
32,300
-155,322
-83% -$1.17M
ELLO icon
89
Ellomay Capital Ltd
ELLO
$270M
$48K 0.01%
5,653
-90,000
-94% -$748K
ABBV icon
90
AbbVie
ABBV
$443B
– –
-362,000
Closed -$21.4M
AOS icon
91
A.O. Smith
AOS
$8.29B
– –
-5,400
Closed -$207K
APTV icon
92
Aptiv
APTV
$12B
– –
-10,065
Closed -$863K
ARWR icon
93
Arrowhead Research
ARWR
$11.9B
– –
-486,000
Closed -$2.99M
AXTA icon
94
Axalta
AXTA
$7.66B
– –
-56,173
Closed -$1.5M
BMRN icon
95
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-3,700
Closed -$388K
BMY icon
96
Bristol-Myers Squibb
BMY
$133B
– –
-121,500
Closed -$8.36M
CHKP icon
97
Check Point Software Technologies
CHKP
$13B
– –
-55,857
Closed -$4.55M
CTSH icon
98
Cognizant
CTSH
$24.9B
– –
-36,600
Closed -$2.2M
DVAX
99
DELISTED
Dynavax Technologies
DVAX
– –
-90,000
Closed -$2.17M
EXEL icon
100
Exelixis
EXEL
$13.3B
– –
-450,000
Closed -$2.54M
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sphera Funds Management held 143 positions worth $461M, down 32% from $683M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sphera Funds Management withdrew a net $108M in Q1 2016, closing 54 positions and reducing 27 holdings. Its most notable exit was AbbVie, an estimated $21.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 61% a quarter earlier, followed by Technology and Utilities.

Against the trend, Sphera Funds Management opened a new position in Viatris worth $13.3M.

  • Sphera Funds Management's largest Q1 2016 buy was Viatris: 287,827 shares worth $13.3M.
  • Sphera Funds Management added most to Shire pic in Q1 2016, an estimated $24.9M increase.
  • Sphera Funds Management's biggest Q1 2016 reduction was Celgene Corp, cutting an estimated $4.86M.
  • Sphera Funds Management fully exited AbbVie in Q1 2016, selling an estimated $21.4M.
  • Sphera Funds Management's ten largest holdings make up 60% of its $461M portfolio in Q1 2016.
  • Sphera Funds Management opened 25 new positions and closed 54 in Q1 2016.
  • Sphera Funds Management's portfolio value fell 32% quarter-over-quarter to $461M.

Based on Sphera Funds Management's 13F filing for Q1 2016, filed 16 May 2016.